- Home
- IMCC vs XBIO Comparison
IMCC vs XBIO Comparison
Compare IMCC & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCC
- XBIO
- Stock Information
- Founded
- IMCC 1980
- XBIO N/A
- Country
- IMCC Israel
- XBIO United States
- Employees
- IMCC N/A
- XBIO N/A
- Industry
- IMCC Medicinal Chemicals and Botanical Products
- XBIO Biotechnology: Pharmaceutical Preparations
- Sector
- IMCC Health Care
- XBIO Health Care
- Exchange
- IMCC Nasdaq
- XBIO Nasdaq
- Market Cap
- IMCC 5.0M
- XBIO 5.8M
- IPO Year
- IMCC N/A
- XBIO N/A
- Fundamental
- Price
- IMCC $2.81
- XBIO $3.66
- Analyst Decision
- IMCC
- XBIO Hold
- Analyst Count
- IMCC 0
- XBIO 1
- Target Price
- IMCC N/A
- XBIO N/A
- AVG Volume (30 Days)
- IMCC 27.2K
- XBIO 30.0K
- Earning Date
- IMCC 11-14-2024
- XBIO 11-12-2024
- Dividend Yield
- IMCC N/A
- XBIO N/A
- EPS Growth
- IMCC N/A
- XBIO N/A
- EPS
- IMCC N/A
- XBIO N/A
- Revenue
- IMCC $38,042,859.00
- XBIO $2,523,427.00
- Revenue This Year
- IMCC $22.59
- XBIO N/A
- Revenue Next Year
- IMCC $20.53
- XBIO N/A
- P/E Ratio
- IMCC N/A
- XBIO N/A
- Revenue Growth
- IMCC N/A
- XBIO 7.15
- 52 Week Low
- IMCC $1.13
- XBIO $2.78
- 52 Week High
- IMCC $8.10
- XBIO $5.20
- Technical
- Relative Strength Index (RSI)
- IMCC 71.25
- XBIO 45.78
- Support Level
- IMCC $1.84
- XBIO $3.58
- Resistance Level
- IMCC $3.34
- XBIO $4.60
- Average True Range (ATR)
- IMCC 0.26
- XBIO 0.41
- MACD
- IMCC 0.10
- XBIO -0.02
- Stochastic Oscillator
- IMCC 64.78
- XBIO 7.48
About IMCC IM Cannabis Corp.
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immune-oncology technologies addressing cancers. The company is also engaged in progressing XCART, a personalized CAR T platform technology. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. The company also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin-resistant endometrial cancer.